Apr 10 |
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
|
Apr 10 |
J&J, Rallybio partner on drug development for rare fetal condition
|
Apr 1 |
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
|
Mar 12 |
Rallybio GAAP EPS of -$0.50
|
Mar 12 |
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
|
Feb 26 |
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
|
Feb 7 |
Jefferies cuts Rallybio to hold, cites lack of near-term catalysts
|
Feb 6 |
Rallybio shares jump 13% on restructuring, cash runway extension
|
Feb 6 |
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
|
Jan 4 |
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
|